Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

In brief

This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.

Key facts

Study ID
NCT03996265
Run by
University of Rochester NCORP Research Base
People needed
422
Starts
2019-06-27
Expected to finish
2026-08-05
Last updated by the study team
2026-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.